Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 . J of Skin [Internet]. 2022 Mar. 4 [cited 2025 Sep. 25];6(2):s2. Available from: https://skin.dermsquared.com/skin/article/view/1517